New drug cocktail aims to tame type 1 diabetes
NCT ID NCT05696366
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a combination of two drugs, sotagliflozin and volagidemab, can improve blood sugar control in adults with type 1 diabetes. The 24 participants will receive both drugs or a placebo in a crossover design. The goal is to see if this approach can help manage the disease more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sotagliflozin and volagidemab
What this could lead to
If successful, this combination could offer a new way to help people with type 1 diabetes better manage their blood sugar and reduce diabetes-related complications.
What could go wrong
This is a small, early-phase trial (Phase 1/2) with only 24 people. The drugs may not work as hoped or could cause side effects. Results may not apply to everyone with type 1 diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC San Diego Altman Clinical & Translational Research Institute
La Jolla, California, 92037, United States